Loading your page…
Marketing-authorisation holder · United States
1 medicine in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Breyanzi4.6ml/vial · Injection | Lisocabtagene maraleucel | United States | Marketed | 2021 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 1 | 1 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
